

*David S. Warner, M.D., Editor*

## An Update on the Pathophysiology of Complex Regional Pain Syndrome

Stephen Bruehl, Ph.D.\*



This article has been selected for the ANESTHESIOLOGY CME Program. Learning objectives and disclosure and ordering information can be found in the CME section at the front of this issue.

### ABSTRACT

Complex regional pain syndrome (CRPS) is a neuropathic pain disorder with significant autonomic features. Few treatments have proven effective, in part, because of a historically poor understanding of the mechanisms underlying the disorder. CRPS research largely conducted during the past decade has substantially increased knowledge regarding its pathophysiologic mechanisms, indicating that they are multifactorial. Both peripheral and central nervous system mechanisms are involved. These include peripheral and central sensitization, inflammation, altered sympathetic and catecholaminergic function, altered somatosensory representation in the brain, genetic factors, and psychophysiologic interactions. Relative contributions of the mechanisms underlying CRPS may differ across patients and even within a patient over time, particularly in the transition from “warm CRPS” (acute) to “cold CRPS” (chronic). Enhanced knowledge regarding the pathophysiology of CRPS increases the possibility of eventually achieving the goal of mechanism-based CRPS diagnosis and treatment.

**C**OMPLEX regional pain syndrome (CRPS) is the current diagnostic label for the syndrome historically referred to as reflex sympathetic dystrophy, causalgia, and a variety of other

terms.<sup>1</sup> It is a chronic neuropathic pain disorder distinguished by significant autonomic features and typically develops in an extremity after acute tissue trauma. In addition to classic neuropathic pain characteristics (intense burning pain, hyperalgesia, and allodynia), CRPS is associated with local edema and changes suggestive of autonomic involvement (altered sweating, skin color, and skin temperature in the affected region). Trophic changes to the skin, hair, and nails and altered motor function (loss of strength, decreased active range of motion, and tremor) may also occur. CRPS is subdivided into CRPS-I (reflex sympathetic dystrophy) and CRPS-II (causalgia), reflecting, respectively, the absence or presence of documented nerve injury.<sup>2</sup> Despite this traditional diagnostic distinction, signs and symptoms of the two CRPS subtypes are similar, and there is no evidence that they differ in terms of pathophysiologic mechanisms or treatment responsiveness.

The results of two epidemiologic studies in the general population<sup>3,4</sup> indicate that at least 50,000 new cases of CRPS-I occur annually in the United States alone.<sup>5</sup> It is more common in women and with increasing age.<sup>3,4</sup> Although CRPS can develop virtually after any (even minimal) injury, the most common initiating events are surgery, fractures, crush injuries, and sprains.<sup>6</sup> CRPS patients experience not only intense pain but also significant functional impairments and psychological distress.<sup>7-11</sup> In clinical settings outside of specialty pain clinics, CRPS may be underrecognized.<sup>12</sup>

CRPS is one of the more challenging chronic pain conditions to treat successfully.<sup>13</sup> There is no definitive medical treatment, and clinical trials have failed to support the efficacy of many commonly used interventions.<sup>14-16</sup> Because of the absence of other effective medical treatments, invasive and expensive palliative interventions are often used, such as spinal cord stimulation and intrathecal drug delivery systems, contributing to the high costs of managing CRPS. Lack of adequate treatments for CRPS has resulted in part from incomplete under-

\* Associate Professor, Department of Anesthesiology, Vanderbilt University School of Medicine, Nashville, Tennessee.

Received from the Department of Anesthesiology, Vanderbilt University School of Medicine, Nashville, Tennessee. Submitted for publication December 17, 2009. Accepted for publication April 8, 2010. Support was provided solely from institutional and/or departmental sources.

Address correspondence to Dr. Bruehl: Vanderbilt University Medical Center, 701 Medical Arts Building, 1211 Twenty-First Avenue South, Nashville, Tennessee 37212. stephen.bruehl@vanderbilt.edu. This article may be accessed for personal use at no charge through the Journal Web site, [www.anesthesiology.org](http://www.anesthesiology.org).

standing of its pathophysiologic mechanisms. Indeed, a National Institutes of Health State-of-the-Science Meeting on CRPS concluded that existing research on mechanisms of human CRPS is inadequate and that it has failed to capture adequately the complex nature of the condition observed in clinical patients.<sup>17</sup> Several issues regarding existing animal models of CRPS will first be briefly addressed, followed by more detailed presentation of current research regarding key mechanisms that may contribute to the clinical syndrome of CRPS.

### Animal Models of CRPS

Although definitive human studies documenting CRPS pathophysiology are the ultimate goal, well-validated animal models of CRPS could also help to elucidate its pathophysiology and to provide opportunities for evaluating new pharmacologic options for CRPS management. Until relatively recently, animal models of CRPS were restricted to general neuropathic pain models, which at best might parallel CRPS-II (causalgia), that is, CRPS associated with clear evidence of a peripheral nerve injury. These models include the sciatic nerve ligation model<sup>18</sup> and the sciatic nerve resection model,<sup>19</sup> both of which can produce allodynia, hyperalgesia, edema, temperature changes, and trophic changes similar to CRPS-II. Although clearly useful as animal models of neuropathic pain in general, they do not adequately reflect CRPS-I, a syndrome of neuropathic pain associated with edema and autonomic features in the absence of clear nerve injury.

Animal models that may better reflect CRPS-I have been developed in the past several years, an important advance given that CRPS-I is much more common than CRPS-II. Availability of such animal models is important because they allow prospective evaluation of pathophysiologic mechanisms of CRPS-I after experimental injury. Two relatively recent models seem to produce a syndrome resembling CRPS-I with no evidence of nerve injury.<sup>20</sup> These models are the postfracture chronic pain model<sup>21</sup> and the ischemic reperfusion injury model (leading to chronic postischemic pain).<sup>22</sup> Evidence supports the potential utility of both models. For example, using the postischemic pain rat model of CRPS-I, enhanced nociceptive firing is observed in response to the presence of norepinephrine,<sup>20</sup> supporting the concept of sympatho-afferent coupling that has been suggested by several human CRPS studies (detailed in Altered SNS Function). Recent work using this model further suggests that a transcription factor, nuclear factor  $\kappa$ B, could play a role in CRPS and may provide an upstream link between increased proinflammatory neuropeptides and increased proinflammatory cytokines in CRPS.<sup>23</sup> This potential mechanism has not yet been investigated in humans, and in this case, the animal model could point toward fruitful avenues of investigation in human CRPS-I patients.

The postfracture rat model of CRPS-I has also shown heuristic value, revealing that proinflammatory neuropeptides and cytokines contribute to allodynia, hyperalgesia, temperature changes, and edema similar to that observed in human CRPS-I.<sup>21,24,25</sup> Despite the research potential of

these animal models of CRPS-I, their validity is not without question. For example, in Wistar rats, neither ischemic reperfusion injury nor sham injury led to significant trophic changes, edema, differences in skin color or temperature, or other signs suggestive of CRPS-I.<sup>26</sup> Additional work is needed to determine the extent to which the various available animal models of CRPS successfully mirror clinical features and mechanisms underlying human CRPS. Moreover, direct comparisons between available animal models of CRPS-I and CRPS-II would be helpful to clarify the validity, advantages, and disadvantages of each. It should be noted that the pathophysiologic mechanisms detailed in the remainder of this review are based on the findings in both animal and human studies, with reliance on the latter where available.

### Pathophysiologic Mechanisms of CRPS

Although multiple attempts have been made to reduce CRPS to a single pathophysiologic mechanism (*e.g.*, sympatho-afferent coupling),<sup>27</sup> it has become increasingly accepted that there are multiple mechanisms involved. Only in the past few years, has it been recognized that CRPS is not simply a sympathetically mediated peripheral pain condition but rather is a disease of the central nervous system as well.<sup>28</sup> Evidence for this comes from the fact that CRPS patients display changes in somatosensory systems processing thermal, tactile, and noxious stimuli, that bilateral sympathetic nervous system (SNS) changes are observed even in patients with unilateral CRPS symptoms and that the somatomotor system may also be affected.<sup>28</sup> There is some evidence that subtypes of CRPS may exist, reflecting differing relative contributions of multiple underlying mechanisms.<sup>29</sup> The remainder of this review will summarize the current findings regarding the CRPS mechanisms most widely accepted and documented in the literature (table 1).

#### Altered Cutaneous Innervation after Injury

It is now believed that even in CRPS-I, some form of initial nerve trauma is an important trigger for the cascade of events leading to CRPS.<sup>30,31</sup> This proposition is supported by the evaluations of skin biopsy samples obtained in patients with CRPS-I, in whom there were no clinical signs of nerve injury.<sup>31,32</sup> In one such study,<sup>31</sup> significantly lower densities of epidermal neurites (up to 29% lower) were observed in CRPS-affected limbs relative to contralateral unaffected limbs, with these changes affecting primarily nociceptive fibers. Similar asymmetry in neurite density was not observed between the affected and unaffected limbs of patients with unilateral non-CRPS pain conditions such as osteoarthritis.<sup>31</sup> Comparable findings were obtained in a separate study. Albrecht *et al.*<sup>32</sup> reported decreased C-fiber and A $\delta$ -fiber density in the affected limbs of CRPS-I patients compared with nonpainful control sites on the same extremity and compared with healthy controls. Abnormal innervation around hair follicles and sweat glands was also observed.<sup>32</sup>

Findings such as those described earlier indicate that CRPS-I, in which there are no clinical signs of peripheral

**Table 1.** Summary of Pathophysiologic Mechanisms that May Contribute to CRPS

Mechanism	Supporting Pattern of Findings
Altered cutaneous innervation	Reduced density of C- and A $\delta$ -fibers in CRPS-affected region <sup>31,32</sup> Altered innervation of hair follicles and sweat glands in CRPS-affected limb <sup>32</sup>
Central sensitization	Increased windup in CRPS patients <sup>37,38</sup>
Peripheral sensitization	Local hyperalgesia in CRPS-affected vs. -unaffected extremity <sup>43</sup> Increased mediators of peripheral sensitization (see Inflammatory Factors later)
Altered SNS function	Bilateral reductions in SNS vasoconstrictive function predict CRPS occurrence prospectively <sup>50,51</sup> Vasoconstriction to cold challenge is absent in acute CRPS but exaggerated in chronic CRPS <sup>46,55,61</sup> Sympatho-afferent coupling <sup>48</sup>
Circulating catecholamines	Lower norepinephrine levels in CRPS-affected vs. -unaffected limb <sup>55,62,63</sup> Exaggerated catecholamine responsiveness because of receptor up-regulation related to reduced SNS outflow <sup>63,64</sup>
Inflammatory factors	Increased local, systemic, and cerebrospinal fluid levels of proinflammatory cytokines, including TNF- $\alpha$ , interleukin-1 $\beta$ , -2, and -6 <sup>72-76</sup> Decreased systemic levels of antiinflammatory cytokines (interleukin-10) <sup>74</sup> Increased systemic levels of proinflammatory neuropeptides, including CGRP, bradykinin, and substance P <sup>80-82</sup> Animal postfracture model of CRPS-I indicates that substance P and TNF- $\alpha$ contribute to key CRPS features <sup>21,24,25</sup>
Brain plasticity	Reduced representation of the CRPS-affected limb in somatosensory cortex <sup>85-89</sup> These alterations are associated with greater pain intensity and hyperalgesia, impaired tactile discrimination, and perception of sensations outside of the nerve distribution stimulated <sup>86,88,91</sup> Altered somatosensory representations may normalize with successful treatment, <sup>87,89</sup> although other brain changes may persist <sup>90</sup>
Genetic factors	In largest CRPS genetic study to date (n = 150 CRPS patients), <sup>109</sup> previously reported associations were confirmed between CRPS and human leukocyte antigen-related alleles <sup>105-109</sup> A TNF- $\alpha$ promoter gene polymorphism is associated with "warm CRPS" <sup>106</sup>
Psychologic factors	Greater preoperative anxiety prospectively predicts acute CRPS symptomatology after total knee arthroplasty <sup>39</sup> Emotional arousal has a greater impact on pain intensity in CRPS than in non-CRPS chronic pain, possibly <i>via</i> associations with catecholamine release <sup>7,119</sup>

CGRP = calcitonin gene-related peptide; CRPS = complex regional pain syndrome; SNS = sympathetic nervous system; TNF = tumor necrosis factor.

nerve damage, is nonetheless associated with significant loss of C-fibers and A $\delta$ -fibers in the affected area.<sup>31,32</sup> Available human studies cannot determine whether this neurite loss is related causally to the injury initiating CRPS, although results of one animal study support this view. A single needle stick injury (18-gauge needle) to the distal nerves in rats led to reductions in nociceptive neuron density of up to 26%,<sup>33</sup> a reduction similar in magnitude to the findings in human CRPS-I patients.<sup>31,32</sup> This animal study highlights the possibility that the altered distal extremity innervation observed in CRPS-I patients may be a result of the injury triggering CRPS. Whether reduced density of nociceptive neurites in human CRPS-I is an epiphenomenon or rather is directly related to expression of other characteristic CRPS signs and symptoms remains to be proven.

### Central Sensitization

Persistent or intense noxious input resulting from tissue damage or nerve injury triggers increased excitability of nociceptive neurons in the spinal cord, a phenomenon termed

central sensitization.<sup>34</sup> Central sensitization is mediated by the nociception-induced release of neuropeptides, such as substance P and bradykinin, and the excitatory amino acid glutamate acting at spinal N-methyl-D-aspartic acid receptors.<sup>34,35</sup> Central sensitization results in exaggerated responses to nociceptive stimuli (hyperalgesia) and permits normally nonpainful stimuli such as light touch or cold to activate nociceptive pathways (allodynia).<sup>34</sup> An objective measure associated with central sensitization is windup, which is reflected in increased excitability of spinal cord neurons that is evoked by repeated brief mechanical or thermal stimulation occurring at a frequency similar to the natural firing rate of nociceptive fibers.<sup>36</sup> CRPS patients display significantly greater windup to repeated stimuli applied to the affected limb than on the contralateral or other limbs.<sup>37,38</sup>

It is not known whether central sensitization precedes, follows, or cooccurs with development of other CRPS signs and symptoms. Previous prospective work found that greater knee pain intensity before undergoing total knee arthroplasty

predicted who developed CRPS at 6-month follow-up.<sup>39</sup> To the extent that higher clinical pain intensity might be a marker of greater central sensitization,<sup>34</sup> these findings suggest the possibility that increased central sensitization might contribute to later development of CRPS. This possibility remains to be tested directly.

### **Peripheral Sensitization**

Although persistent nociceptive input after tissue injury triggers central sensitization processes in the spinal cord and brain, the initial tissue trauma itself also elicits local peripheral sensitization.<sup>40</sup> After tissue trauma, primary afferent fibers in the injured area release several pronociceptive neuropeptides (*e.g.*, substance P, bradykinin; see Inflammatory Factors for additional information) that increase background firing of nociceptors, increase firing in response to nociceptive stimuli, and decrease the firing threshold for thermal and mechanical stimuli.<sup>40,41</sup> These latter two effects contribute, respectively, to the hyperalgesia and allodynia that are key diagnostic features of CRPS.<sup>42</sup> Local hyperalgesia likely resulting from both peripheral and central sensitization can be seen in findings of significantly reduced acute pain thresholds in the affected extremity of chronic CRPS patients compared with their unaffected extremity.<sup>43</sup> Given that peripheral sensitization is triggered by the initial tissue trauma leading to persistent pain, it is likely that it is present in CRPS patients very early in the development of the condition. However, its role in the development of CRPS has not been tested directly.

### **Altered SNS Function**

Historically, it was assumed that common autonomic features of CRPS, such as a cool, bluish limb, were the result of vasoconstriction reflecting excessive SNS outflow and that the pain in CRPS was sympathetically maintained.<sup>27</sup> The presumed role of excessive SNS outflow in key CRPS characteristics was the traditional rationale for clinical use of selective sympatholytic blocks (*e.g.*, stellate ganglion) for pain and symptom relief in CRPS patients. Possible reasons for links between CRPS pain and SNS activity have been suggested. Animal studies indicate that after nerve trauma, adrenergic receptors are expressed on nociceptive fibers, providing one mechanism by which SNS outflow might directly trigger nociceptive signals.<sup>44,45</sup> Given that even in CRPS-I, some type of nerve trauma seems to be involved in onset of the condition,<sup>30,31</sup> expression of adrenergic receptors on nociceptive fibers might help to explain the impact of SNS outflow on CRPS pain.

Expression of adrenergic receptors on nociceptive fibers after injury may contribute to sympatho-afferent coupling, a phenomenon demonstrated in several human studies. For example, forehead cooling (which elicits systemic SNS vasoconstrictor activation) and intradermal injection of norepinephrine both significantly increase CRPS pain intensity.<sup>46,47</sup> Experimental manipulations of SNS vasoconstrictor function using whole body cooling and warming also support sympatho-afferent

coupling.<sup>48</sup> Specifically, in patients with sympathetically maintained CRPS pain, high (relative to low) SNS activity increased spontaneous pain by 22% and increased the spatial extent of dynamic and punctate hyperalgesia by 42 and 27%, respectively.<sup>48</sup> Follow-up work using this same methodology suggests that SNS innervation of deep somatic structures may be more important than cutaneous SNS innervation as a determinant of sympatho-afferent coupling in the acute phase of CRPS.<sup>49</sup> Although using a cross-sectional rather than prospective design, examination of the pattern of results in this latter study as a function of pain duration suggested that the SNS-mediated component of CRPS pain may diminish over time.<sup>49</sup>

Although the findings regarding sympatho-afferent coupling indicate that CRPS pain and other symptoms may in some cases be linked to SNS activity, they do not necessarily imply that excessive SNS outflow is responsible. Indeed, the only prospective human studies on the issue of SNS function in CRPS do not support this common clinical assumption. Schürmann *et al.*<sup>50</sup> assessed SNS function (peripheral vasoconstrictor responses induced by contralateral limb cooling) in unilateral fracture patients shortly after injury. Development of CRPS 12 weeks later was predicted by early impairments in SNS function (reduced vasoconstrictor response). Impaired SNS function was observed before the onset of CRPS on both the affected and unaffected sides, suggesting systemic alterations in SNS regulation shortly after injury. These findings are confirmed by more recent work examining CRPS incidence after carpal tunnel surgery in patients with previously resolved CRPS.<sup>51</sup> Among asymptomatic former CRPS patients who displayed impaired vasoconstrictive responses to SNS challenge before surgery, 73% had a postsurgical recurrence of CRPS. In contrast, among patients showing normal SNS vasoconstrictive responses before surgery, only 13% developed a recurrence of CRPS. As in the study by Schürmann *et al.*,<sup>50</sup> SNS impairments in the former group were generally bilateral (82% patients). Cross-sectional studies in patients with acute CRPS further confirm findings of impaired SNS function relative to pain patients without CRPS.<sup>52,53</sup> Reduced SNS function (and the resulting excessive vasodilation) in early acute CRPS would help to account for the observation that acute CRPS is most often associated with a warm, red extremity rather than the cool, bluish presentation often noted in chronic CRPS.<sup>50,54</sup>

Other work indicates that whole body cooling and warming produce symmetrical vasoconstriction and vasodilation in healthy controls and non-CRPS pain patients but elicit dysfunctional SNS thermoregulatory activity in CRPS patients.<sup>55</sup> Vasoconstriction to cold challenge in this study was absent in patients with acute CRPS ("warm CRPS"), but it was exaggerated in patients with chronic CRPS ("cold CRPS").<sup>55</sup> Although controlled studies have failed to find evidence to support Bonica's<sup>56</sup> traditional three sequential stages of CRPS,<sup>29,57</sup> a transition from a warm, red CRPS presentation to a cold, bluish CRPS presentation is common as CRPS moves from the acute to the chronic state.<sup>55</sup> It

should be noted that vascular abnormalities in CRPS may be impacted by non-SNS mechanisms as well. Studies suggest that chronic CRPS patients exhibit impaired endothelial-dependent vasodilatory function and altered levels of endothelin-1, nitric oxide, and nitric oxide synthase.<sup>32,49,58–60</sup>

### Role of Circulating Catecholamines

Changes in the pattern of CRPS signs and symptoms as the condition moves from the acute to the chronic phase may in part reflect a progression in catecholaminergic mechanisms. Despite evidence that chronic CRPS patients often display exaggerated vasoconstriction to cold challenge on the affected side,<sup>46,55,61</sup> they nonetheless exhibit lower norepinephrine levels on the affected side compared with the unaffected side.<sup>55,62,63</sup> These lower norepinephrine levels may imply diminished local SNS outflow. Taken together, these findings suggest that the exaggerated vasoconstrictive responses observed in chronic CRPS patients may occur even in the context of reduced SNS outflow. It is believed that this paradoxical pattern may be a result of receptor up-regulation, that is, the decreased SNS outflow noted earlier in acute CRPS would be expected to lead to compensatory up-regulation of peripheral adrenergic receptors.<sup>63,64</sup> The resulting supersensitivity to circulating catecholamines may then lead to exaggerated sweating and vasoconstriction on exposure to circulating catecholamines (*e.g.*, released in response to life stress or pain itself) and thus the characteristic cool, blue, sweaty extremity typically seen in chronic CRPS patients.<sup>65</sup> Whether vasoconstriction in CRPS is related to direct SNS actions, circulating catecholamines acting at up-regulated receptors, endothelial dysfunction, or reduced nitric oxide levels, this vasoconstriction may contribute to development of trophic changes often associated with CRPS *via* local tissue hypoxia.<sup>66</sup>

### Inflammatory Factors

Findings in several small clinical trials indicate that corticosteroids significantly improved symptoms in some patients with acute CRPS, suggesting the possibility that inflammatory mechanisms might contribute to CRPS, at least in the acute phase.<sup>67,68</sup> Recent work supports this hypothesis. Inflammation contributing to CRPS can arise from two sources. Classic inflammatory mechanisms can contribute through actions of immune cells such as lymphocytes and mast cells, which, after tissue trauma, secrete proinflammatory cytokines including interleukin-1 $\beta$ , -2, -6, and tumor necrosis factor (TNF)- $\alpha$ .<sup>40</sup> One effect of such substances is to increase plasma extravasation in tissue, thereby producing localized edema similar to that observed in CRPS.

Neurogenic inflammation may also occur, mediated by release of proinflammatory cytokines and neuropeptides directly from nociceptive fibers in response to various triggers, including nerve injury.<sup>69</sup> Neuropeptide mediators involved in neurogenic inflammation include substance P, calcitonin gene-related peptide (CGRP), and bradykinin (which is also involved in initiating cytokine release<sup>70</sup>). These neuropep-

tides both increase plasma extravasation and produce vasodilation and thus can produce the warm, red, edematous extremity most characteristic of acute CRPS.<sup>30</sup> Substance P and TNF- $\alpha$  activate osteoclasts that could contribute to the patchy osteoporosis frequently noted radiographically in CRPS patients, and CGRP can increase hair growth and increase sweating responses—both features sometimes noted in CRPS patients.<sup>30,71</sup> Proinflammatory cytokines and neuropeptides also produce peripheral sensitization leading to increased nociceptive responsiveness.

A number of studies have specifically examined the associations between CRPS and proinflammatory and antiinflammatory cytokines. Several studies indicate that compared with pain-free controls and non-CRPS pain patients, CRPS patients display significant increases in proinflammatory cytokines (TNF- $\alpha$ , interleukin-1 $\beta$ , -2, and -6) in local blister fluid, circulating plasma, and cerebrospinal fluid.<sup>72–76</sup> CRPS patients also seem to have reduced systemic levels of antiinflammatory cytokines (interleukin-10) compared with controls, which may also contribute to increased inflammation in the condition.<sup>74</sup> Increased TNF- $\alpha$  levels do impact on sensory CRPS symptoms. CRPS-I patients with hyperalgesia had significantly higher plasma levels of soluble TNF- $\alpha$  receptor type I than CRPS patients without hyperalgesia,<sup>73</sup> and neuropathic pain patients with allodynia display higher plasma TNF- $\alpha$  levels than similar patients without allodynia.<sup>77</sup> TNF- $\alpha$  is a key cytokine because not only does it have direct pronociceptive actions but it also induces production of other cytokines involved in inflammation, including interleukin-1 $\beta$  and -6.<sup>78</sup> Interestingly, administration of a TNF- $\alpha$  antibody (infliximab) may produce notable reductions in CRPS symptoms in some patients.<sup>79</sup>

Other work supports an association between CRPS and proinflammatory neuropeptides. Birklein *et al.*<sup>80</sup> reported increased systemic CGRP in CRPS patients compared with healthy controls. CGRP can produce vasodilatation, edema, and increased sweating—all features associated with acute CRPS.<sup>80</sup> Successful treatment of CRPS was associated with reduced CGRP levels and decreased clinical signs of inflammation.<sup>80</sup> Another study also found significantly higher plasma levels of CGRP in CRPS patients compared with pain-free controls and further noted significant increases in plasma bradykinin.<sup>81</sup> Other work indicates that plasma levels of substance P are significantly higher in CRPS patients than in healthy controls.<sup>82</sup> Moreover, intradermal application of substance P on either the affected or unaffected limb in CRPS patients has been shown to induce protein extravasation in that limb, whereas it does not do so in healthy controls.<sup>83</sup> These authors suggested that the capacity to inactivate substance P was impaired in CRPS patients. In summary, inflammatory factors can account for a number of the cardinal features of CRPS, particularly in the acute “warm” phase. Findings in clinical research that edema is less likely with increasing CRPS duration are also consistent with a greater role for inflammatory mechanisms in the acute

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.